辛伐他汀对稳定性冠心病患者的血清高敏C-反应蛋白水平的影响

首都医科大学学报 ›› 2008, Vol. 29 ›› Issue (4): 490-492.

辛伐他汀对稳定性冠心病患者的血清高敏C-反应蛋白水平的影响

王珊, 谭静, 华琦

首都医科大学宣武医院心脏科

收稿日期:2008-02-16 修回日期:1900-01-01 出版日期:2008-08-24 发布日期:2008-08-24
通讯作者: 华琦

Effect of Simvastatin on High Sensitivity C-reactive Protein in Serum of Patients with Stable Coronary Artery Disease

Wang Shan, Tan Jing, Hua Qi

Department of Cardiology, Xuanwu Hospital, Capital Medical University

Received:2008-02-16 Revised:1900-01-01 Online:2008-08-24 Published:2008-08-24

摘要/Abstract

摘要： 目的探讨辛伐他汀20mg/d对稳定性冠心病患者降脂达标率及血清高敏C-反应蛋白(hs-CRP)水平的影响.方法 34例稳定性冠心病患者(其中男26例,女8例),年龄41～79岁,平均(64.4±11.3)岁,服用辛伐他汀20mg/d,疗程12周.治疗前、治疗4周及12周时分别检测血清总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、丙氨酸氨基转移酶(ALT)、门冬氨酸氨基转移酶(AST)、肌酐(Cr)、尿素氮(BUN)、尿酸(UA)、血糖(GLU)、肌酸激酶(CPK)及血清高敏C-反应蛋白(hs-CRP).结果辛伐他汀20mg/d治疗12周降低TC、LDL-C、TG的幅度分别为34.8%、46.1%、24.7%;升高HDL-C2.0%,使76.5%冠心病患者LDL-C降至目标值,并可显著降低hs-CRP水平(P=0.018).结论辛伐他汀20mg/d治疗冠心病患者有较高的降脂达标率,并可能有利于抑制炎症反应.

关键词: 辛伐他汀, C-反应蛋白, 冠心病

Abstract: Objective To explore the effect of simvastatin on high sensitivity C-reactive protein in serum of patients with stable coronary artery disease.Methods 34 patients with stable coronary artery disease at the age of 41～79 years old(26 males and 8 females,mean age at 64.4±11.3 years old) were given 20 mg/d simvastatin at night.The therapeutic course was 12 weeks.Fasting serum total cholesterol(TC),triglyceride(TG),high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C),high sensitivity C-reactive protein(hs-CRP) and other biochemistry data were examined before and after 4 and 12 weeks' treatment.Results After 12 weeks' treatment,TC,LDL-C,TG significantly decreased by 34.8%,46.1% and 24.7%,but HDL-C increased by 2.0% slightly.76.5% patients could reach Chinese standard level of LDL-C,and the Hs-CRP level decreased significantly(P=0.018).Conclusion The use of 20 mg/d simvastatin is efficacious at lowering LDL-C levels and allowing patients to achieve their goal to low cholesterol level,and may be beneficial to inhibiting inflammatory response in patients with stable coronary artery disease.

Key words: simvastatin, C-reactive protein, coronary artery disease

中图分类号:

R541.4

王珊;谭静;华琦. 辛伐他汀对稳定性冠心病患者的血清高敏C-反应蛋白水平的影响[J]. 首都医科大学学报, 2008, 29(4): 490-492.

Wang Shan;Tan Jing;Hua Qi. Effect of Simvastatin on High Sensitivity C-reactive Protein in Serum of Patients with Stable Coronary Artery Disease[J]. Journal of Capital Medical University, 2008, 29(4): 490-492.

[1]	苏云娟, 王京京, 韩晓涛, 刘海燕, 陈永福, 杨柳, 吴其明. 青年男性冠心病的危险因素及Framingham风险评分的预测价值[J]. 首都医科大学学报, 2022, 43(1): 143-148.
[2]	王立秋, 殷昌斌, 李家伟. 血清同型半胱氨酸、脂蛋白(a)和超敏C反应蛋白联合检测对脑梗死患者的临床意义[J]. 首都医科大学学报, 2015, 36(5): 782-785.
[3]	谷珊珊, 王蒨, 董薇, 焦建, 苏航, 付瑛. 心脏融合显像定量评价功能相关冠状动脉狭窄的临床研究[J]. 首都医科大学学报, 2013, 34(1): 36-42.
[4]	南楠;金泽宁;杨泽. 脂联素基因多态性与2型糖尿病合并冠心病的关联研究[J]. 首都医科大学学报, 2012, 33(4): 421-426.
[5]	吴修信;李立新;廖品君;苑媛. 急性脑梗死患者血清淀粉样蛋白A的临床和预后价值[J]. 首都医科大学学报, 2012, 33(2): 255-258.
[6]	许骥;郝恒剑;胡少东;尹春琳. 不稳定心绞痛患者高敏C-反应蛋白与冠状动脉病变程度的关系[J]. 首都医科大学学报, 2010, 31(1): 106-108.
[7]	高敬;华琦;王彩荣;李晓辉;高承梅. 实时三维超声心动图评价冠心病患者左心功能[J]. 首都医科大学学报, 2008, 29(4): 487-489.
[8]	陈可冀;薛梅;殷惠军. 血小板活化与冠状动脉粥样硬化性心脏病和血瘀证的关系[J]. 首都医科大学学报, 2008, 29(3): 266-269.
[9]	杨毅;袁申元;潘素芳;钱宁. 体质量指数与糖尿病、冠心病、脑卒中发病率的相关性[J]. 首都医科大学学报, 2006, 27(5): 669-671.
[10]	谢英;李曦;田雨贤;蒋朝辉. 辛伐他汀对老年冠心病患者血脂和脂质比值的调节作用[J]. 首都医科大学学报, 2006, 27(4): 501-503.
[11]	赵秀丽;周延明;杨金奎;李金城;张慧;吴莹;张仁汉;胡大一. 格列吡嗪控释片治疗冠心病合并2型糖尿病的临床研究[J]. 首都医科大学学报, 2006, 27(1): 78-80.
[12]	刘琦;常志文. 辛伐他汀对血脂、载脂蛋白A₁、B₁₀₀及hs-CRP的影响[J]. 首都医科大学学报, 2005, 26(4): 474-475.
[13]	陈欣;杨明;邹凤军;丁五麟;张小航;王青;高亢;潘国忠;尹朝霞;韩凌;胡文泽;岑强. 腺苷超声心动图负荷试验诊断冠心病的应用价值[J]. 首都医科大学学报, 2005, 26(2): 136-139.
[14]	刘惠兰;姚英;李国刚;张香玲;孙懿;翟林. 炎症与血透患者颈动脉粥样硬化关系的研究[J]. 首都医科大学学报, 2005, 26(2): 179-182.
[15]	张雪莲;傅汉菁;潘素芳. 糖尿病慢性大血管并发症与vWF的关系[J]. 首都医科大学学报, 2004, 25(4): 488-492.